louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00753324: Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia
Official title: Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia (Impact of HAART to Prevent Pediatric AIDS in Rural Zambia).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: HIV Infections
Keywords: PMTCT
HAART
Pregnancy
HIV Infection
HIV Transmission
HIV Seronegativity
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
Collaborators: name: Doris Duke Charitable Foundation
First posted: 2008-09-16
Enrollment: 284
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The investigators will enroll a cohort of HIV-infected pregnant women accessing PMTCT services, to better understand the incremental benefits (e.g. reduction in HIV transmission, improvements in HIV-free survival) and risks (e.g. drug toxicities) of the routine HAART strategy, in comparison to HIV-infected pregnant women accessing the Zambian Standard of Care services.

The investigators will test the hypothesis that routine use of HAART produces significant reductions in HIV transmission rates, with only minimal side effects.


Eligibility criteria: Inclusion Criteria:

* HIV infected
* Pregnant women
* Ability to provide informed consent.
* Meets eligibility criteria for HAART initiation

Exclusion Criteria:

* Unwillingness to provide informed consent
* Below the age of legal consent

Primary outcomes:
measure: HIV Infection
timeFrame: 12 months
Secondary outcomes:
measure: HIV Infection
timeFrame: 6 weeks, 6 months and 24 months
measure: Infant survival
timeFrame: 12 and 24 months
measure: HIV-free survival
timeFrame: 12 months and 24 months
measure: Incidence of maternal toxicity to HAART regimens
timeFrame: 24 months
Other outcomes:
Locations:
city: Lusaka
country: Zambia
facility: CIDRZ
Study officials:
affiliation: Centre for Infectious Disease Research in Zambia
name: Benjamin Chi, M.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gartland MG, Chintu NT, Li MS, Lembalemba MK, Mulenga SN, Bweupe M, Musonda P, Stringer EM, Stringer JS, Chi BH. Field effectiveness of combination antiretroviral prophylaxis for the prevention of mother-to-child HIV transmission in rural Zambia. AIDS. 2013 May 15;27(8):1253-62. doi: 10.1097/QAD.0b013e32835e3937.
Clinical trial NCT06726824: NEOnatal Multiexposure to Medical Devices Plasticizers: Endocrine Disruption MIXture Effects and Neurodevelopmental Disorders
Official title: NEOnatal Multiexposure to Medical Devices Plasticizers: Endocrine Disruption MIXture Effects and Neurodevelopmental Disorders
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Neurodevelopmental Disorder (Diagnosis)
Keywords: Neurodevelopmental disorder
Multiexposure
Medical devices
Plasticizers
Cocktail effects
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2024-12-10
Enrollment: 97
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients will be recruted in Clermont-Ferrand And Lille centers. They are ambulatory patients whose parents Will be contacted by phone by research team to plan, if they accept to participate, a teleconsultation

Brief summary: The goal of this observational study is to evaluate the neurodevelopment of children from the ARMED NEO cohort through the ASQ3 score.

Dose the multiexposure to medical devices plasticizers during the neonatal intensive care unit stay increases the risk of developing neurodevelopmental disorders ? Patients (their parents) will complète several questionnaires (ASQ3, environnemental survey, EPICES score) during a planned teleconsultation with the research team


Eligibility criteria: Inclusion Criteria:

* Live patient who participated in the ARMED NEO study, included at the Clermont-Ferrand or Lille hospitals
* Patient whose holders of parental authority have expressed their non-opposition to their participation in the study

Exclusion Criteria:

* Patient whose guardians have expressed opposition to their participation in the study
* Patient with no French speaking parent
* patient

Primary outcomes:
measure: ASQ3® score translated into an overall numerical score corresponding to the total of 5 dimensions of the ASQ3 test.
timeFrame: From enrollment to the end of the teleconsultation
measure: ASQ3® score translated into an overall numerical score corresponding to the total of 5 dimensions of the ASQ3 test.
timeFrame: From en recollement to the end of the teleconsultation
Secondary outcomes:
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU Clermont-Ferrand
city: Lille
country: France
facility: CHU de Lille
Study officials:
References:
Clinical trial NCT02707224: Clinical Trial to Compare the Pharmacokinetics of DP-R208
Official title: A Randomized, Single-dose, Open, Crossover Clinical Trial to Compare the Pharmacokinetics of DP-R208 (Candesartan Cilexetil and Rosuvastatin Calcium Fixed Dose Combinations) in Comparison to Each Component Administered Alone in Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: DP-R208
Lead sponsor: Alvogen Korea
Sponsor class: INDUSTRY
First posted: 2016-03-14
Enrollment: 40
Sex: MALE
Minimum age (years): 19
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: A randomized, single-dose, open, crossover clinical trial to compare the pharmacokinetics of DP-R208 (Candesartan cilexetil and Rosuvastatin calcium fixed dose combinations) in comparison to each component administered alone in healthy male volunteers


Eligibility criteria: Inclusion Criteria:

* BMI 17.5\~30.5
* signed the informed consent form prior to the study participation

Exclusion Criteria:

* Clinically significant disease
* Previously donate whole blood within 60 days or component blood within 14 days
* Clinically significant allergic disease
* Taken IP in other trial within 90 days
* An impossible one who participates in clinical trial by investigator's decision including laboratory test result

Primary outcomes:
measure: Peak Plasma Concentration (Cmax)
timeFrame: up to 72 hours post dose
measure: Area under the plasma concentration versus time curve (AUC)
timeFrame: up to 72 hours post dose
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Chonbuk National University Hospital
name: Min-Gul Kim, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02141724: Wheelchair Positioning and Pain in Neuromuscular Patients
Official title: Assessment of Wheelchair Positioning and Pain in Adults Patients With Neuromuscular Disorder
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adult Patients With Neuromuscular Disorders Using Wheelchair
Keywords: Neuromuscular
Wheelchair
Pain
Bedsore
Trouble postural
Lead sponsor: Centre d'Investigation Clinique et Technologique 805
Sponsor class: OTHER
Collaborators: name: Fondation Garches
name: Association Française contre les Myopathies (AFM), Paris
First posted: 2014-05-19
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults patients with neuromuscular disordres using wheelchair.

Brief summary: A retrospective study with the patients having a positioning consultation at hospital, between 2009 and 2014. In every neuromuscular disorder, the investigators describe the population seen in consultation, the aim of consultation, the postural problem observed in wheelchair, pain when sitting in wheelchair, and pressure ulcer.

Detailed description: Postural problem is described with MCPAA (Measure of Postural Control in Sitting Position, created by B. GAGNON, physiotherapist in Quebec) : we look at pelvic obliquity, pelvic rotation, pelvic anteversion or retroversion, trunk slope and rotation, kyphotic or scoliotic posture, neck posture and legs posture. We evaluate if these deformities are soft, moderate or severe, and if they are relievable

Eligibility criteria: Inclusion Criteria:

* Adult patient with neuromuscular disorder
* using wheelchair
* Patient having a positioning consultation in GARCHES Hospital

Exclusion Criteria:

* refusal to participate to the protocol
* pregnancy

Primary outcomes:
measure: Postural disorders
timeFrame: 2h
Secondary outcomes:
measure: Number of patient with Pain
timeFrame: 15 minutes
Other outcomes:
measure: Bedsores
timeFrame: 15 minutes
Locations:
city: Garches
country: France
facility: Hopital Raymond Poincare
Study officials:
affiliation: HOPITAL RAYMOND POINCARE
name: PELLEGRINI Nadine, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05302024: Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Official title: Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: a Phase 2, Open-label, Single-arm Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Immune Thrombocytopenia
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2022-03-31
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A phase 2, open-label, single-arm study to evaluate the efficacy and safety of iguratimod for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP)

Detailed description: The investigators are undertaking an open-label, single-arm study of 100 adults with steroid-resistant/ relapse ITP in China. Patients were received Iguratimod treatment. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study.

Eligibility criteria: Inclusion Criteria:

* Primary immune thrombocytopenia (ITP) confirmed by excluding other supervened causes of thrombocytopenia;
* Platelet count of less than 30×10\^9/L at enrollment;
* Patients who did not achieve a sustained response to treatment with full-dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid-tapering or after its discontinuation;
* 18 years older;

Exclusion Criteria:

* Secondary immune thrombocytopenia (e.g., patients with HIV, HCV, Helicobacter pylori infection or patients with systemic lupus erythematosus)
* Congestive heart failure
* Severe arrhythmia
* Nursing or pregnant women
* Aspartate aminotransferase and alanine transaminase levels ≥ 3× the upper limit of the normal threshold criteria
* Creatinine or serum bilirubin levels each 1•5 times or more than the normal range
* Active or previous malignancy
* Unable to do blood routine test for the sake of time, distance, economic issues or other reasons.

Primary outcomes:
measure: Durable response
timeFrame: 6 months
Secondary outcomes:
measure: Initial response
timeFrame: 1 month
measure: Remission
timeFrame: 12 months
measure: Time to response
timeFrame: 12 months
measure: Bleeding
timeFrame: 12 months
measure: Adverse events
timeFrame: 12 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Insititute of Hematology, Peking University People's Hospital
state: Beijing
Study officials:
affiliation: Peking University People's Hospital
name: Xiao-Hui Zhang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01272024: An Intervention to Improve Outcomes in Patients With Advanced Cancer
Official title: An Intervention to Improve Outcomes in Patients With Advanced Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Cancer
Keywords: clinical trial
symptom education
advanced cancer
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Institute of Nursing Research (NINR)
First posted: 2011-01-07
Enrollment: 146
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: 1.) To integrate discharge planning into an intervention provided by advanced practice nurses (APRNs)for patients with advanced cancer, 2.) To evaluate the effects of the intervention, and 3.) To explore the reach, adoption, and implementation of the intervention to facilitate the transition of patients from surgery/biopsy/chemotherapy to medical oncology in a comprehensive cancer center.


Eligibility criteria: Inclusion Criteria:

* primary diagnosis of advanced lung, GI, Head \& Neck, and Lung cancers
* post-surgical/or post-biopsy with physician's order for cancer treatment
* age 21 years or older
* lives within 50 of Yale New Haven Hospital
* has 2 or more co-morbid conditions
* has an emotional distress thermometer score of greater than or equal to 4-

Exclusion Criteria:

Primary outcomes:
measure: Uncertainty
timeFrame: 1 month post baseline
measure: Uncertainty
timeFrame: 3 months post-baseline
Secondary outcomes:
measure: HADS- Anxiety
timeFrame: 1 month post baseline
measure: HADS-Anxiety
timeFrame: 3 months post baseline.
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale New Haven Hospital/Smilow Cancer Hospital
state: Connecticut
Study officials:
affiliation: Yale University
name: Ruth McCorkle, RN, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03094624: Auditory Deficits in Congenital Amusia (AMUSIE CONGENITALE)
Official title: Auditory Perceptual and Memory Deficits in Congenital Amusia: Studies of Cerebral Correlates With MEG, Anatomical MRI and Functional MRI
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Amusia, Congenital
Keywords: Amusia
Audition
Short-term memory
Emotions
EEG
MEG
MRI
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2017-03-29
Enrollment: 230
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The project studies auditory deficits in congenital amusia at the behavioral and neurophysiological levels.

The auditory processes investigated are pitch discrimination, short-term memory, sound-induced emotions. To characterize auditory deficits in the amusic population, neuropsychological assessments are combined with neurophysiological markers (Electro-encephalography: EEG, Magneto-encephalography: MEG, Magnetic Resonance Imaging: MRI).


Eligibility criteria: Inclusion Criteria:

* Aged from 18 to 70 years' old
* French
* Compatibility IRM / MEG (no metal in the body)
* Motivation to participate effectively in the project
* No neurological or psychiatric history
* No severe hearing loss
* Informed consent to participate in the study
* For Amusic participants: participant diagnosed amusic by the MBEA (Montreal Battery of Evaluation of Amusia)
* For Control participants: matched in age, sex, education, music education, laterality, non-amusic (controlled with the MBEA)

Exclusion Criteria:

* Age below 18 or above 70
* Non-Francophone volunteers.
* MRI scanning not possible: artificial cardiac pacemaker, insulin pump, metallic prosthesis, intra-cerebral clip, claustrophobia
* MEG acquisition not possible: large heads, neurostimulator, metal in the head or the body.
* Pregnant or breast-feeding women

Primary outcomes:
measure: Correct answers to the neuropsychological tests
timeFrame: Day 1
measure: Neuropsychological tests reaction times
timeFrame: Day 1
measure: Neurophysiological tests EEG
timeFrame: Day 1
measure: Neurophysiological tests MEG
timeFrame: Day 1
measure: Neurophysiological tests MRI
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon, Hôpital Edouard Herriot
Study officials:
affiliation: Hospices Civils de Lyon
name: Julien JUNG, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01253824: Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers
Official title: Pharmacodynamics of NPC-01( 1mg Norethisterone and 0.02mg Ethinyl Estradiol) and IKH-01( 1mg Norethisterone and 0.035mg Ethinyl Estradiol); Effect of NPC-01 and IKH-01 on Serum Concentrations of Estradiol, Progesterone, FSH and LH.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Healthy
Keywords: NPC-01
IKH-01
Pharmacodynamics
Norethisterone
Ethinyl Estradiol
Estradiol
Progesterone
FSH
LH
Lead sponsor: Nobelpharma
Sponsor class: INDUSTRY
First posted: 2010-12-03
Enrollment: 14
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the serum levels of estradiol, progesterone, FSH and LH in NPC-01 or IKH-01 one treatment cycle with those in before and after administration cycle.


Eligibility criteria: Inclusion Criteria:

* Healthy female aged between 20 to 35 years
* BMI:18.0-26.0

Exclusion Criteria:

* Females who are pregnant
* Drug use affecting sex hormone secretion

Primary outcomes:
measure: Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
timeFrame: Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles
measure: Comparing Progesterone AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
timeFrame: Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles
Secondary outcomes:
measure: Comparing FSH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
timeFrame: Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles
measure: Comparing LH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA))
timeFrame: Day 3, 6, 9, 12, 15, 18, 21, 24 of menstrual cycles
Other outcomes:
Locations:
Study officials:
affiliation: Hyogo Prefectural AWAJI Hospital
name: Takefumi Matuo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05604924: Virtual Reality Training Simulator for Cesarean Section
Official title: A Clinical Trial to Evaluate Effectiveness of Virtual Reality Training Simulator for Cesarean Section
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Virtual Reality
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2022-11-03
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The goal of this is to determine the effectiveness of virtual reality training simulator for cesarean section.

Evaluate the effect of using VR surgery on the self-confidence and knowledge of cesarean section procedures.

Detailed description: A single center randomized controlled trial (RCT) was performed. The participants were obstetrics residents, fellows and residents in other majors with limited experience in performing cesarean section. The primary outcome measures were the self-assessment scores of trainee confidence using a virtual reality training and an objective assessment of the cognitive skills. The participants were randomly divided into a study group of VR training group and a control group. Participants in the study group used the VR application. The control group participants used similar content in a standard PowerPoint presentation on a laptop.

Eligibility criteria: Inclusion Criteria:

* Residents and fellows receiving training at Seoul National University Bundang Hospital and who wish to participate in this study

Exclusion Criteria:

* If trainee refuse to participate in this study

Primary outcomes:
measure: improvement on the knowledge of cesarean section procedures.
timeFrame: 1 month after examination
measure: improvement on the self-confidence of cesarean section procedures.
timeFrame: 1 month after examination
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeong-gi Do
Study officials:
References:
Clinical trial NCT00628524: Homburg Cream & Sugar Study
Official title: Prospective Investigation of the Influence of Triglyceride Tolerance on Cardiovascular Outcomes in Patients With Coronary Artery Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Diabetes
Metabolic Syndrome
Glucose Tolerance
Hyperlipidemia
Lead sponsor: University Hospital, Saarland
Sponsor class: OTHER
First posted: 2008-03-05
Enrollment: 514
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: \> 500 consecutive patients with stable coronary artery disease being treated in the cardiology department of the university hospital.

Brief summary: The purpose of this study is to prospectivly analyze the correlation of triglyceride tolerance and glucose tolerance with cardiovascular morbidity and mortality in patients with stable coronary artery disease within 18 months and to determine, whether measurement of triglyceride tolerance can discriminate patients at risk for cardiovascular events.


Eligibility criteria: Inclusion Criteria:

* Stable CAD

Exclusion Criteria:

* Acute Coronary Syndrom
* Relevant Arrhythmias
* Severe valvular heart disease
* Decompensated heart failure
* Severe inflammtory disease (infectious, rheumatoid)
* Metabolic diseases (e.g. thyroid)
* Inability to swallow
* Liver or kidney failure
* Lactose intolerance
* Fat intolerance (e.g. chronic pancreatitis, gall stones)
* Malignant Disease
* Psychiatric Diseases (including alcohol / drug abuse)
* Pregnancy

Primary outcomes:
measure: Parameters of triglyceride tolerance and glucose tolerance in correlation to cardiovascular events, cardiovascular mortality, total mortality.
timeFrame: 48 months after inclusion.
Secondary outcomes:
measure: Waist-to-Hip ratio, nutrition protocol, physical activity, non-invasive endothelial function, body fat composition, other biomarkers of lipid and glucose metabolism.
timeFrame: Directly after inclusion.
Other outcomes:
Locations:
city: Homburg
country: Germany
facility: University Hospital Homburg / Saar - Cardiology Department
state: Saarland
Study officials:
affiliation: University Hospital, Saarland
name: Ulrich Laufs, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Katzmann JL, Werner CM, Stojakovic T, Marz W, Scharnagl H, Laufs U. Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study. Lipids Health Dis. 2020 May 30;19(1):116. doi: 10.1186/s12944-020-01293-9.
citation: Hoffmann MM, Werner C, Bohm M, Laufs U, Winkler K. Association of secreted frizzled-related protein 4 (SFRP4) with type 2 diabetes in patients with stable coronary artery disease. Cardiovasc Diabetol. 2014 Nov 19;13:155. doi: 10.1186/s12933-014-0155-2.